Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2023-02-21 Regulatory Filings
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce unscheduled material events or corporate changes. The content describes an announcement of FDA clearance for a clinical trial and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document length is 3340 characters, which is relatively short and primarily serves as an announcement rather than a full report. According to the rules, such announcements with attached press releases are classified as Regulatory Filings (RNS) rather than financial reports or other specific categories.
2023-02-21 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement Amendment No. 1 filed with the SEC by Chemomab Therapeutics Ltd. It is a preliminary prospectus for an offering of American Depositary Shares and Warrants. The text includes detailed information about the offering, company overview, risk factors, use of proceeds, capitalization, dilution, dividend policy, management discussion and analysis, executive compensation, security ownership, description of share capital and securities offered, underwriting, legal matters, and financial statements. This type of filing is related to capital raising and securities registration rather than a financial report or earnings release. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or any other financial report. It is a capital markets filing related to financing and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, consistent with a capital raising filing.
2023-02-21 English
8-K
Management Reports Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 21, 2023, by Chemomab Therapeutics Ltd. It discloses the company's consolidated audited financial statements for the fiscal year ended December 31, 2022, along with Management's Discussion and Analysis (MD&A) of financial condition and results of operations. The text includes detailed financial data, operating results, expenses breakdown, and forward-looking statements. It explicitly states that the company intends to file its Annual Report on Form 10-K by March 31, 2023, indicating this 8-K is a current report disclosing year-end financial results and MD&A but not the full 10-K itself. The presence of detailed financial results and MD&A in this filing aligns with the characteristics of a Management Reports (MDA) document, which provides management's detailed explanation of financial results and business trends. It is not an Earnings Release (ER) as it contains more comprehensive financial discussion and is not just key highlights. It is not the full Annual Report (10-K) but a current report with financial results and MD&A. Therefore, the best classification is Management Reports (MDA).
2023-02-21 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes a preliminary prospectus with detailed information about the company, the offering, risk factors, use of proceeds, capitalization, dilution, executive compensation, and other relevant disclosures for investors. This type of filing is related to capital raising activities and securities registration, not an annual report, earnings release, or other financial report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but a full registration statement with detailed offering information.
2023-01-13 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 11, 2023. It includes a Regulation FD Disclosure indicating an updated corporate presentation is attached as Exhibit 99.1. The text does not contain detailed financial statements or analysis but rather references the attached presentation. The document length is 3308 characters, which is relatively short and consistent with an announcement rather than a full report. The key content is the disclosure of a corporate presentation, which aligns with an Investor Presentation (IP) filing type. Therefore, the document is best classified as an Investor Presentation (IP).
2023-01-11 English
Director's Dealing 2023
Director's Dealing
2023-01-05 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.